PLUR PLURI INC

Pluri Shortlisted for CDMO of the Year Award by Advanced Therapies Awards 2025

Pluri Shortlisted for CDMO of the Year Award by Advanced Therapies Awards 2025

PluriCDMO™, the Company’s contract development and manufacturing organization, recognized as a leading manufacturing collaborator offering scalability and mass scale production to a growing number of innovative life science companies

HAIFA, Israel, Dec. 09, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: PLUR) (TASE:PLUR) ("Pluri" or the “Company"), a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today announced that its ™ business, launched earlier this year, has been shortlisted for the CDMO of the Year Award by the prestigious .

“This recognition is particularly meaningful as it comes less than a year after we launched our CDMO division,” stated Yaky Yanay, Chief Executive Officer and President of Pluri. “I couldn’t be prouder of what we’ve accomplished together at Pluri including signing agreements with valued clients and making strides towards our vision of supporting transformative therapies for patients worldwide. We’re excited to continue expanding our CDMO work and contributing to this dynamic and impactful industry. A heartfelt thank you to the Advanced Therapies Awards team for this recognition and congratulations to all the outstanding finalists.”

 in January 2024, leveraging its proprietary knowledge, cutting-edge technology and cell therapy production facility on behalf of clients. PluriCDMO™ clients gain access to Pluri’s 47,000 square foot state-of-the-art GMP facilities, and to Pluri’s patented bioreactor system, which enables 3D cell expansion at mass scale via a fully controlled, automated and validated process. For more information visit  or contact .

About Pluri Inc.

Pluri™ is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global well-being and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of challenges— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective and consistent from batch to batch. Pluri currently operates in the regenerative medicine, foodtech and agtech fields. The Company also offers Contract Development and Manufacturing Organization services. Pluri establishes partnerships that are aimed to leverage the Company’s proprietary 3D cell-based technology across various industries that require effective, mass cell production. To learn more, visit us at  or follow Pluri on  and  (formerly known as Twitter).

Safe Harbor Statement

This press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluri is using forward-looking statements when it discusses its vision, continued expansion of its CDMO work and its contribution to the industry. These forward-looking statements and their implications are based on the current expectations of the management of Pluri only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements about Pluri: changes in technology and market requirements; Pluri may encounter delays or obstacles in launching and/or successfully completing its clinical trials, if necessary; its products may not be approved by regulatory agencies, its technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; it may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with its processes; its products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; its patents may not be sufficient; its products may harm recipients or consumers; changes in legislation with an adverse impact; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluri to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluri reference is made to Pluri's reports filed from time to time with the Securities and Exchange Commission.

Contacts

Investors: 

Israel Media: Shachar Yental at 

U.S. Media: Jessica Daitch at 



EN
09/12/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PLURI INC

 PRESS RELEASE

Pluri CEO Issues Shareholder Letter Highlighting Strategic Growth, Inn...

Pluri CEO Issues Shareholder Letter Highlighting Strategic Growth, Innovation, and Global Market Expansion Major milestones include entry into cultivated cacao and coffee markets and progress toward commercial-scale productionCompany reports nearly 400% revenue growth in the first nine months of fiscal year 2025 compared to the same period in fiscal year 2024, driven by its CDMO and AgTech businesses, and is advancing new food tech partnerships and licensing opportunities HAIFA, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq, TASE: PLUR) (“Pluri” or the “Company”), a leadi...

 PRESS RELEASE

Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFo...

Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd. Acquisition of approximately 71% stake in Kokomodo Ltd.Acquisition uniquely combines Pluri's mass-scale cell production expertise with Kokomodo Ltd.’s ability to craft real, controlled, climate-resilient cacao using cellular agriculture technology HAIFA, Israel, April 28, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures...

 PRESS RELEASE

Pluri Announces Expansion of Intellectual Property Portfolio with Two ...

Pluri Announces Expansion of Intellectual Property Portfolio with Two Granted Patents for 3D Expansion of Immune Cells in the United States and Israel Latest granted patents reinforce Pluri’s position as a leader in Mucosal-Associated Invariant T (“MAIT”) cell-based cell therapies for solid cancersPluri’s MAIT platform enables commercial scale production of powerful immune cells as a potential first-in-class, ready to use, “off-the-shelf” therapy for cancer patientsPluri’s MAIT platform addresses the global immune cell engineering market, projected to reach approximately by 2030, and the g...

Ari Zoldan
  • Ari Zoldan

Pluri Inc. - Initiation of Coverage

Pluri Inc. is a biotechnology company leveraging proprietary 3D cell expansion technology to provide scalable cell-based solutions across regenerative medicine, food technology, contract development and manufacturing (CDMO), and agricultural sectors. The company's innovative PluriMatrix platform, utilizing an automated cGMP-approved bioreactor system, ensures high-quality, consistent, and cost-effective industrial-scale cell production applicable to pharmaceuticals, biologics, cultivated foods, ...

 PRESS RELEASE

Pluri Announces Exclusive Collaboration Agreement with Hemafund to Enh...

Pluri Announces Exclusive Collaboration Agreement with Hemafund to Enhance Ukraine's Radiation Emergency Preparedness Strategic initiative to address Ukraine’s urgent need for radiation countermeasures Hemafund's infrastructure ensures secure storage and rapid deployment of emergency treatments Collaboration may potentially generate over $100 million in value for both parties HAIFA, Israel, March 05, 2025 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotechnology company leveraging its proprietary platform for cell-based solutions to cr...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch